Predictive Power of Baseline [F]FDG PET/CT for Adverse Events in DLBCL Patients Undergoing CAR-T Cell Therapy.

: Evaluation of the predictive potential of pre-CAR-T [F]FDG PET/CT in Diffuse Large B-Cell Lymphoma (DLBCL) patients concerning Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS). : Eighteen DLBCL patients (mean age: 60 ± 12 years) who underwent pre-therapeutic [F]FDG-PET/CT and CAR-T cell therapy were retrospectively included. Median follow-up time was ten months (IQR6-16) after CAR-T cell infusion.

Anti-harassment policies across Canadian and international medical programs: strengths, areas for improvement, and a need for standardization.

Background/purpose: Medical trainee harassment is a global issue that has led to a multitude of detrimental effects. An important area of consideration is whether harassment policies are clear and available to all medical trainees globally. We aimed to develop a standardized rubric for evaluating anti-harassment policies and assess policies across Canadian medical schools and top international universities to identify strengths and areas for improvement.

CD137 Signaling Modulates Vein Graft Atherosclerosis by Driving T-Cell Activation and Regulating Intraplaque Angiogenesis.

Atherosclerotic vein graft failure still presents a major problem. T-cells have been identified as one of the most abundant immune cell subset in atherosclerotic plaques. Their role, however, remains only partly understood.

Synovial fluid as a complex molecular pool contributing to knee osteoarthritis.

The main homeostatic function of the synovial fluid is joint lubrication. However, during knee osteoarthritis (KOA), synovial fluid becomes modified with drivers of disease that contribute to symptoms (pain) and joint-related pathology. Acting as a sink of factors from both systemic circulation and local tissues, including articular cartilage, subchondral bone, synovium, and the infrapatellar fat pad, the synovial fluid enables bidirectional communication promoting KOA pathogenesis.

[F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis.

Objectives: The aim of this study is to evaluate the potential of [F]FDG-PET/CT in terms of prognostic value and treatment monitoring in relapsed / refractory diffuse large B-cell lymphoma (DLBCL)-patients treated with chimeric antigen receptor T-cell (CAR-T) therapy.

Material & Methods: Forty-eight [F]FDG-PET/CT scans, acquired at pre-defined time points (t - t) of 18 DLBCL-patients (mean age: 60 ± 12 years) treated with CAR-T cell therapy were retrospectively enrolled. Median time of follow-up was ten months (IQR 6-16) following CAR-T cell infusion.